Skip to content

Group-Based Contingency Management for Substance Abuse Treatment - 1

Group-Based Contingency Management for Substance Abuse Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00249717
Enrollment
312
Registered
2005-11-07
Start date
2005-05-31
Completion date
2010-01-31
Last updated
2011-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Abuse

Keywords

Contingency management, Substance abuse treatment

Brief summary

The purpose of this study is to evaluate the efficacy of prize-based contingency management (CM) when administered exclusively in groups. Substance dependent patients (N=360) at community-based treatment programs are randomly assigned to one of two conditions: (a) standard, non-CM treatment or (b) standard treatment plus prize CM delivered in groups. In the CM condition, patients earn the opportunity to win prizes for attending groups and submitting drug-free biological specimens. Substance use and psychosocial problems are measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up evaluations. We also assess patient characteristics that may be associated with improved outcomes within and across conditions.

Interventions

BEHAVIORALContingency management

Receive rewards (prizes) abstinence and attendance

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
UConn Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 years * current DSM-IV diagnosis of cocaine, opioid or alcohol abuse or dependence * willing to provide breath and urine samples for 12 weeks * English speaking * willing to sign informed consent

Exclusion criteria

* serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) * dementia (\<23 on the Mini Mental State Exam; Folstein et al. 1975) * in recovery from pathological gambling

Design outcomes

Primary

MeasureTime frame
Drug usebaseline and at each follow-up
Retentioneach follow-up

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026